The Latest Breaking News from Pfizer

CNBC Celsius Withdraws Motion To Rehire CFO

With climate change spurring more cases of tick-borne Lyme disease, drugmaker Valneva is betting big on a vaccine as it looks beyond disappointing sales of its COVID shot.

Someone with a lot of money to spend has taken a bullish stance on Pfizer (NYSE:PFE). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Paxlovid good at stopping hospitalisation for high-risk groups, despite occasional rebound

The world is watching the Jan. 6 hearings in the United States in dismay and contemplating the possible end of the American democratic experiment.

21.2 million Americans received their second booster by the end of July.

After taking Paxlovid, Biden tested negative for several days, then positive. He's not the only one

The “living with COVID” strategy being pursued by many countries relies heavily on two key pillars. First, that vaccines continue to protect most people from severe disease. And second, that where they don’t, people will receive antiviral treatments. But are the antivirals currently available sufficiently effective, accessible and durable?

The Food and Drug Administration reportedly has a new strategy for rolling out new booster shots that should bring needed clarity to COVID vaccination in the U.S. Going forward, most Americans will get the same advice about when to get their next shots.